ライフサイエンスコーパス: tumor lesion

1 distribution in normal tissues and uptake in tumor lesions.

2 fically reflect monocyte activity in primary tumor lesions.

3 mixture of NiSO4 and (68)Ga to simulate hot tumor lesions.

4 a 10-fold increase in the number and size of tumor lesions.

5 ia selective depletion of T reg cells within tumor lesions.

6 ng and providing information on ER status of tumor lesions.

7 multiple immune suppressions in established tumor lesions.

8 ced the production of CXCL10 and CCL5 in all tumor lesions.

9 ppressor cells and regulatory T cells in the tumor lesions.

10 pression of programmed death-ligand 1 in the tumor lesions.

11 king of tumor antigen-specific CTLs into CNS tumor lesions.

12 at the CNT1 protein was indeed absent in the tumor lesions.

13 growth associated with the establishment of tumor lesions.

14 and immunosuppressive potential of MDSCs in tumor lesions.

15 ges were collected to determine targeting of tumor lesions.

16 the uptake and retention of radioactivity in tumor lesions.

17 In the remaining patients, 19% of tumor lesions 1 cm or greater known by CT were visualize

18 populations within the same tumor or between tumor lesions, a phenomenon termed tumor heterogeneity.

19 Without Id2, Rb(+/-) mice have fewer early tumor lesions and a markedly decreased proliferation rat

20 B16 melanoma model to profile chemokines in tumor lesions and assess their impact on gammadelta TIL

21 exploits the natural anti-Gal Ab to destroy tumor lesions and convert them into an endogenous vaccin

22 rostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinic

23 erm blockade, increases the frequency of pre-tumor lesions and creates a tumor-permissive microenviro

24 ay be the most beneficial in detecting small tumor lesions and disease staging.

25 tor is induced in multiple cell types within tumor lesions and its increased expression is associated

26 nostimulatory mAbs to act both on irradiated tumor lesions and on distant, nonirradiated tumor sites.

27 adjacent mucosa were similar to those in the tumor lesions and significantly higher than those in the

28 ed oHSV alone, effectively tracks metastatic tumor lesions and significantly prolongs the survival of

29 one may exacerbate immune suppression in the tumor lesions and that methods to improve the tumor micr

30 The favorable immunologic changes in tumor lesions and the improvement of antitumor effects f

31 C PET/CT was true-positive in 5 patients (10 tumor lesions) and was false-positive in 1 patient.

32 ressions are mutually exclusive in migratory tumor lesions, and GBM patients with MSI1(high)/TNS3(low

33 Because tumor lesions are a complex mixture of cell types, we hy

34 and Pten+/-Tsc2+/- mice, whereas TSC-related tumor lesions are invariably associated with Tsc2 loss o

35 o favorable effects on distant nonirradiated tumor lesions as observed in transplanted MC38 (colorect

36 s indicated a uniform presence of KSHV in KS tumor lesions as revealed by polymerase chain reaction a

37 radioligand accumulation was seen in primary tumor lesions as well as in metastases.

38 e uptake of (188)Re-liposome was detected in tumor lesions but not in surrounding normal lung tissues

39 alone but not ultrasound identified 2 of 10 tumor lesions, but in both patients (68)Ga-DOTATOC-PET/C

40 ination resulted in profound infiltration of tumor lesions by CD8(+) (but not CD4(+)) T cells, in a c

41 8)Ga-NOTA-AE105, and SUVs were obtained from tumor lesions by manually drawing volumes of interest in

42 ER expression in tumor lesions can be visualized by (18)F-fluoroestradiol

43 diation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG2

44 nteraction for the treatment of KS and other tumor lesions, exhibiting hyperactive mTOR pathway funct

45 )-5-methylcytosine (l-(18)F-FMAC) to profile tumor lesions for both dCK and CDA enzymatic activities;

46 Analyses of tumor lesions from 38 Ugandan KS patients indicated a un

47 -SD) peak standardized uptake value in index tumor lesions from 6.4 +/- 3.9 to 9.1 +/- 5.6 (P = 0.037

48 e of BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be useful

49 Metabolic tumor activity, defined as tumor lesion glycolysis (TLG*) on (18)F-FDG PET, was mea

50 vacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV(max) (ma

51 by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and so

52 man herpesvirus type 8 have been found in KS tumor lesions in high frequency.

53 d been also shown that ABT-510 could regress tumor lesions in pet dogs or cause unexpected stabilizat

54 Seven patients (25%) showed new tumor lesions in the FRL after PVE, of whom 3 patients (

55 h biopsies further confirmed the presence of tumor lesions in the mouse lungs.

56 ild-type mice were competent to migrate into tumor lesions in vivo.

57 the colon of mutant mice spontaneously, and tumor lesions, including invasive carcinoma, arose in th

58 Tumor lesion is characterized as chronic indolent inflam

59 Targeting of all known tumor lesions < 0.5 cm [corrected] in diameter was possi

60 ad minimal residual or small-volume disease (tumor lesions < or = 3 cm in diameter).

61 ses in the regulation of inflammation within tumor lesions, making the targeting of matrix metallopro

62 e most prominent (18)F-FDG uptake (reference tumor lesion): mG1, tumor-to-liver ratio of maximum stan

63 s depicted by S100A9 activity in the primary tumor lesion mirrored the tumor's metastatic behavior.

64 ients (68)Ga-DOTATOC-PET/CT revealed further tumor lesions not detected on CT alone.

65 Expression of DKK1 and CKAP4 was frequent in tumor lesions of human pancreatic and lung cancers, and

66 spectrum of cancer cells present in a given tumor lesion or patient.

67 The reactive stroma surrounding tumor lesions performs critical roles ranging from suppo

68 slational response and cell proliferation in tumor lesions, pointing to mTOR inhibition as a therapeu

69 fusion protein or agonist mAb into EphA2(+) tumor lesions promotes EphA2 degradation in situ, this s

70 lasting 7 months before multiple plaque and tumor lesions recurred, along with the development of in

71 Of 53 representative tumor lesions selected at 3 h after injection, 47 lesion

72 , scans at 3 h after injection detected more tumor lesions than at 1 h after injection.

73 mice causes multiple hyperproliferative and tumor lesions that strikingly resemble Cowden's disease.

74 tion in vivo to detect orthotopic pancreatic tumor lesions through active targeting of the EGF recept

75 sive methods that can detect DCK activity in tumor lesions throughout the body could circumvent these

76 1/Tc1-like proinflammatory milieu within the tumor lesion to boost the effector phase of immune respo

77 tration, had sufficient isotope retention in tumor lesions to make external imaging possible.

78 urvival advantage in situ when injected into tumor lesions, to be found in approximation with regions

79 s possible in nine patients and at least one tumor lesion was evident in all patients.

80 SUVmax on day 4 in tumor lesions was 4.6 (range, 1.5-13.9) versus a median

81 The median SUVmax of 94 tumor lesions was 7.3 (range, 1.6-59.5).

82 se in NK cell number in organ parenchyma and tumor lesions was correlated to an increase in the numbe

83 When a LSIR within tumor lesions was detected on diffusion-weighted images

84 The SUVmax of tumor lesions was determined using region-of-interest an

85 ip between the mass and absorbed dose of the tumor lesions was observed.

86 e of several organs and of 53 representative tumor lesions was performed in 15 patients at 1 and 3 h

87 Uptake in organs and tumor lesions was quantified and compared by calculation

88 Tumor lesions were assessed by computed tomography scan

89 Tumor lesions were assessed every 6 weeks, and patients

90 At completion of imaging, suspected tumor lesions were dissected for histopathologic confirm

91 For each patient, up to 7 tumor lesions were evaluated.

92 Tumor lesions were found in the colons of most Fn14(-/-)

93 The SUVmax and contrast of 149 tumor lesions were measured in 69 patients with patholog

94 Although tumor lesions were smaller in Kit(V558;T669I/+) mice tha

95 In 4 of the 14 patients entered, no tumor lesions were visualized with (89)Zr-bevacizumab PE

96 ves to identify heterogeneous uptake between tumor lesions, whereas subcentimeter intralesional heter

97 n of carbonic anhydrase IX (CAIX)-expressing tumor lesions with chimeric monoclonal antibody (mAb) gi

98 prevents the beam from being targeted to the tumor lesion without also irradiating the artery wall.